All News
You get more general autoimmune disease in seropos RA, right?
Not compared to seroneg RA, as it so happens (incidence and point prevalence).
If anything, it leans the other way - what number of things is seroneg RA, anyway?
DANBIO data POS0313 #EULAR2021 @RheumNow https://t.co/mKJQ2jjCU4
David Liew drdavidliew ( View Tweet)
Video: Psoriatic Arthritis Highlights from #EULAR2021 Dr. Jack Cush
https://t.co/xedmiZKOd5 https://t.co/AShEze5rFy
Links:
Dr. John Cush RheumNow ( View Tweet)
Find our #EULAR2021 psoriatic arthritis coverage in one place.
https://t.co/NzB2e2Vfwb https://t.co/P8TfUxfA3F
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Jack Cush reviews highlight presentations from Virtual #EULAR2021.
https://t.co/yjId7QNRRR
Links:
Dr. John Cush RheumNow ( View Tweet)
Novel TYK2 Inhibitor Efficacious for Treatment of Psoriatic Arthritis by Dr. Meral K El Ramahi (@MeralElRamahiMD ) #EULAR2021
https://t.co/l6YnJvuPdi
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, and Janssen. All content chosen by RheumNow & its faculty.
Dr. John Cush RheumNow ( View Tweet)
Video: Personalization of PsA Treatment: Dr. Robert Chao (@doctorRBC ) #EULAR2021
https://t.co/7FmZ4BzHwp
Links:
Dr. John Cush RheumNow ( View Tweet)
Combination vs. Sequential Therapy for the Treatment of Lupus Nephritis by Dr. Kathryn Dao ( @KDAO2011 )
#EULAR2021
https://t.co/0d1bxBlUS0
Links:
Dr. John Cush RheumNow ( View Tweet)
Video: How Can We Help our Patients with Sjogren's? Dr. Janet Pope (@Janetbirdope ) #EULAR2021
https://t.co/dHIrEBs1Rc
Links:
Dr. John Cush RheumNow ( View Tweet)
Artificial intelligence brings clarity to early bony changes in inflammatory arthritis by Dr. David Liew
https://t.co/RPH3k2Gz0W
#EULAR2021
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, & Janssen. All content chosen by RheumNow and its Faculty.
Dr. John Cush RheumNow ( View Tweet)
POS0192
BL prognostic factors of achieving MDA in 77 early PsA treated #T2T strategy.
See forest plot below. Rather sobering results. It seems nearly fullfilling MDA at baseline is associated with fullfilling MDA at 12 months.
More useful predictors needed
#EULAR2021 @RheumNow https://t.co/7U65Nt3Woj
Paul Studenic Stiddyo ( View Tweet)
How common is #burnout among rheumatologists? Dr Maldonado surveyed N=297 in Latin America using Maslach Burnout Inventory. 57% had burnout. Associated with younger,long hours,⬇️satisfaction, depression,⬇️wage,comorbidities. Let's support each other #EULAR2021 #POS0302 @RheumNow https://t.co/QOA2xsDZen
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2021 POS1019
What does remission mean in AxSpA?
Physician's perception impacted most by:
⭐️Morning stiffness
⭐️Axial pain
⭐️NSAID use
⭐️Extra-artic manif
❌Fatigue less impact
Many subjective factors w/o consensus in AxSpA
@RheumNow
Eric Dein ejdein1 ( View Tweet)
Looking for all #EULAR2021 JAK/TYK2 coverage? We've got it all in one place on RheumNow.
https://t.co/6diCyfyJxI https://t.co/p26PU77aAm https://t.co/VYijM3X2aL
Dr. John Cush RheumNow ( View Tweet)
Are We Consistent in Making a SpA Diagnosis? Dr. Eric Dein ( @ejdein1 ) #EULAR2021
https://t.co/yuer9njuTe https://t.co/gBQ6qwkxvo
Links:
Dr. John Cush RheumNow ( View Tweet)
Attention bosses!
AxSpA patients who were older and worse disease activity associated with more sick leave
⭐️male gender and higher education associated with less sick leave
Abs#POS0238
#EULAR2021 @RheumNow https://t.co/aSs0BCHjau
Robert B Chao, MD doctorRBC ( View Tweet)
EULAR 2021 - Day 2 Podcasts
Check out this compilation of our EULAR 2021 Day 2 broadcasts below.
You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.
https://t.co/GskToSkfLk https://t.co/nF2FkHgBtu
Links:
Dr. John Cush RheumNow ( View Tweet)
New GRAPPA 2021 PsO and PsA Treatment Recommendations by Dr. Rachel Tate ( @uptoTate )
The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021.
Read more.
https://t.co/AnHQGA8aKs https://t.co/yJbymc9csR
Links:
Dr. John Cush RheumNow ( View Tweet)
Caveats:
-secondary analysis (consider exploratory)
-unclear clinical significance (modest ΔeGFR)
-baseline CrCl 40+ (do NOT use in advanced CKD)
-systemic rheumatic diseases excluded (unethical to randomize to PBO for 2 years)
-generalizability (all had CVD, M>F, mean age 66)
Jeffrey Sparks MD MMSc jeffsparks ( View Tweet)
